OncoMatch/Clinical Trials/NCT02390518
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
Is NCT02390518 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for brain metastases.
This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Clinically confirmed brain metastases by CT or MRI criteria
Prior therapy
Cannot have received: whole/partial brain irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02390518 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior whole/partial brain irradiation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify